CLEO DIAGNOSTICS (ASX:COV)
Cleo Diagnostics (the Company) is a medical diagnostics entity focused on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer.
SUMMARY OF THE INITIAL PUBLIC OFFERING (IPO)
Eligibility
The IPO is open to:
- Retail, sophisticated and professional investors pursuant to a Prospectus issued by the Company for the purposes of Chapter 6D of the Corporations Act 2001 (Cth).
Initial Public Offer details
- The Company seeks to raise $12.0 million by way of an IPO of 60.0 million shares (Securities) pursuant to a Replacement Prospectus issued by the Company (the Offer) for the purposes of Chapter 6D of the Corporations Act 2001 (Cth).
- Taylor Collison Limited is acting as sole Lead Manager to the IPO.
Offer Price
- $0.20 per Security (Offer Price)
Please refer to the Replacement Prospectus for further details.
Link to Prospectus: www.cleodx.com/prospectus
COMPANY HIGHLIGHTS
- A simple blood test developed for early detection of Ovarian Cancer
- Significant global total addressable cancer diagnostics market opportunity
- Technology underpinned by over 10 years of Research and Development at Hudson Research Institute and two clinical studies with IP protection in place
- Advanced R&D stage with near term commercialisation prospect
- Staged execution strategy focused on an achievable pathway to target markets
- Experienced leadership team with credentials to execute
Key Facts:
Ovarian cancer is the most deadly of all cancers that affect women
It is often asymptomatic and goes undetected until the advanced stages, when the cancer is widespread
Only 29% of women will survive beyond 5 years when diagnosed in the advanced stages
There is no early detection test for ovarian cancer — a pap smear does not detect ovarian cancer
Diagnosis is only made following radical surgery to remove the ovaries.
Contact details:
Elvis Jurcevic
Investor Relations
CLEO Diagnostics
+61408268271
ej@cleodx.com